Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "National"

2120 News Found

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions


Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing
News | March 14, 2026

Co-Diagnostics bags key Japanese patent, bolstering global push for rapid PCR testing

The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process


World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
Healthcare | March 12, 2026

World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India

Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally


BPL Medical Tech acquires South Korea’s Yozma BMtech
News | March 12, 2026

BPL Medical Tech acquires South Korea’s Yozma BMtech

Launches advanced bone density systems in India & Dubai


India tackles rare diseases head-on at landmark summit in New Delhi
News | March 12, 2026

India tackles rare diseases head-on at landmark summit in New Delhi

Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration


UK pushes space-made medicines from orbit to patients with new support package
R&D | March 10, 2026

UK pushes space-made medicines from orbit to patients with new support package

The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen